Literature DB >> 30190873

The role of radiation therapy in the management of cutaneous melanoma.

Charlene E Kan1, David B Mansur1.   

Abstract

The local treatment of cutaneous melanoma with surgical excision is well-established; however, the role of adjuvant radiation is not well-defined. Characteristics of the primary melanoma can indicate a higher local recurrence risk and thus warrant consideration of adjuvant treatment to the primary site. Management of the lymph node regions has been studied in some recent clinical trials, especially with the advent of sentinel lymph node procedures. We will review the indications for radiation to the primary site as well as lymph node regions based on the available data.

Entities:  

Keywords:  melanoma; radiation therapy; sentinel lymph node

Year:  2016        PMID: 30190873      PMCID: PMC6094658          DOI: 10.2217/mmt.15.41

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  51 in total

Review 1.  Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.

Authors:  Donald L Morton
Journal:  Clin Exp Metastasis       Date:  2012-06-24       Impact factor: 5.150

2.  Frequency of nonsentinel lymph node metastasis in melanoma.

Authors:  Kelly M McMasters; Sandra L Wong; Michael J Edwards; Celia Chao; Merrick I Ross; R Dirk Noyes; Vicki Viar; Patricia B Cerrito; Douglas S Reintgen
Journal:  Ann Surg Oncol       Date:  2002-03       Impact factor: 5.344

3.  Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial.

Authors:  C P Karakousis; C M Balch; M M Urist; M M Ross; T J Smith; A A Bartolucci
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

4.  Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study.

Authors:  F H Sim; W F Taylor; D J Pritchard; E H Soule
Journal:  Mayo Clin Proc       Date:  1986-09       Impact factor: 7.616

5.  Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma).

Authors:  J Conley; R Lattes; W Orr
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

6.  Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm.

Authors:  G Cohn-Cedermark; L E Rutqvist; R Andersson; M Breivald; C Ingvar; H Johansson; P E Jönsson; L Krysander; C Lindholm; U Ringborg
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

7.  Neurotropic melanoma. A variant of desmoplastic melanoma.

Authors:  R J Reed; D D Leonard
Journal:  Am J Surg Pathol       Date:  1979-08       Impact factor: 6.394

8.  Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases.

Authors:  James Y Chen; George Hruby; Richard A Scolyer; Rajmohan Murali; Angela Hong; Patrick Fitzgerald; Trang T Pham; Michael J Quinn; John F Thompson
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

9.  Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma.

Authors:  Roy Vongtama; Afshin Safa; David Gallardo; Thomas Calcaterra; Guy Juillard
Journal:  Head Neck       Date:  2003-06       Impact factor: 3.147

10.  Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck.

Authors:  Mark D Bonnen; Matthew T Ballo; Jeffrey N Myers; Adam S Garden; Eduardo M Diaz; Jeffrey E Gershenwald; William H Morrison; Jeffrey E Lee; Mary Jane Oswald; Merrick I Ross; K Kian Ang
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

View more
  1 in total

1.  Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era.

Authors:  Richard J Straker; Yun Song; John N Lukens; Giorgos C Karakousis; James Sun; Adrienne B Shannon; Leah S Cohen; Elnara Muradova; Hala Daou; Kate Krause; Siming Li; Dennie T Frederick; Kristen E Rhodin; David M Brizel; Genevieve M Boland; Georgia M Beasley; Evan J Wuthrick; Vernon K Sondak; Jonathan S Zager; Alexander Lin
Journal:  Ann Surg Oncol       Date:  2020-11-23       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.